Targeted Delivery of DNA Topoisomerase Inhibitor SN38 to Intracranial Tumors of Glioblastoma Using Sub‐5 Ultrafine Iron Oxide Nanoparticles (adv. Healthcare Mater. 14/2022)
Advanced healthcare materials/Advanced Healthcare Materials(2022)
摘要
Theranostics The study in article number 2102816 by Hui Mao and co-workers reports systemic and targeted delivery of sub-5 nm theranostic iron oxide nanoparticles carrying the anti-cancer topoisomerase I inhibitor, SN38, to the intracranial tumors of glioblastoma via the enhanced permeability and retention effect and tumor integrin targeting, leading to improved efficacy of tumor growth inhibition.
更多查看译文
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要